David McMullin

David McMullin serves as Chief Business Officer at Anumana, where he leverages over two decades of experience in corporate development, strategic planning, commercialization, and operations to drive the company’s mission of transforming healthcare through AI-driven innovation. Prior to his role at Anumana, David served as Chief Strategy Officer at nference, where he has been instrumental in developing strategies that bridge AI technology with real-world healthcare applications, including the inception of Anumana.

Prior to Anumana, David was Chief Business Officer at Aldeyra Therapeutics, a $600 million publicly traded biotechnology company where he helped raise more than $225 million to develop novel immuno-mediated-therapies. Earlier, he led Internal Medicine U.S. at Shire plc, a $1.4 billion rare disease commercial business unit. Shire was subsequently acquired by Takeda. Before Shire, David worked at Novartis as a leading global executive with more than a decade of experience in roles of increasing responsibilities across strategy, sales, marketing, and operations, managing product launches and large-scale strategic initiatives.

David holds an MBA with high distinction as a Baker Scholar from Harvard University and dual bachelor degrees with high distinction in Economics and Food Science and Nutrition from Brigham Young University.